Author's posts
Collins booted from Energy & Commerce amid insider trading charges
A major player in 340B drug discount reforms, Rep. Chris Collins (R-N.Y.) can’t serve on the House Energy & Commerce Committee, a key health committee, until federal charges of insider trading are resolved.
Rockwell Medical settles with former CEO, CFO, 2 directors for $1.5 million
Rockwell Medical has hired a new CEO after reaching a settlement that includes $1.5 million in payments to two former top executives and two directors over disagreements on how to sell Triferic, the company’s most promising drug.
Value-based purchasing programs tougher for academic hospitals
A Navigant study found 24% of academic medical centers received penalties for their performance on three of the CMS’ value-based payment programs in fiscal 2018 while 13.7% of community hospitals received penalties.
Study finds immigrants use fewer U.S. healthcare resources
A study to be published Tuesday in the International Journal of Health Services finds that immigrants use far less healthcare resources than persons born in the U.S.
Medicare Advantage change may lower Part B drug prices
The CMS is waiving an Obama-era guidance that prohibited Medicare Advantage plans from imposing prior authorization requirements on Part B drugs.
Patients who accepted infected kidneys cured of hepatitis C
Some patients in desperate need of a kidney transplant participated in a bold experiment where they received organs infected with hepatitis C. The gamble paid off.
States draw sharp limits on association health plans
State insurance regulators have expressed confusion and worry over the Trump administration’s new rule expanding association plans, with some issuing emergency rules and guidances limiting their operations.
Tenet CEO: Conifer buyer should pay for value we’ve added
Tenet Healthcare CEO Ron Rittenmeyer said his hospital chain has improved the performance on its revenue cycle subsidiary, Conifer, enough to justify a higher price.
Carl Icahn urges investors to vote down Cigna-Express Scripts merger
Billionaire activist investor Carl Icahn is urging stockholders to vote against the pending $67 billion merger between Cigna Corp. and Express Scripts, arguing the nation’s largest PBM faces mounting regulatory threats.
Study finds U.S. healthcare would benefit from more immigrants
A study to be published Tuesday in the International Journal of Health Services finds that immigrants use far less health care than compared to persons born in the U.S.
